Email bulletins

Archive

March 2020

  • Liver specialists offer guidance on COVID-19 risks in liver patients
  • Are people with chronic liver disease at higher risk of severe COVID-19 symptoms?
  • Advice on coronavirus (SARS-CoV-2 / COVID-19) for people with viral hepatitis or liver disease
  • All adults ages 18 to 79 should be screened for hepatitis C
  • London sets out route map for hepatitis C elimination
  • HIV-positive people with fatty liver disease are at high risk for fibrosis
  • EASL postpones International Liver Congress 2020 until August
  • Epclusa approved for children aged six and over in United States
  • Is this your copy of the infohep news bulletin?

February 2020

  • Hepatitis C treatment and prevention failing to reach people most affected
  • Increase in clean needle and syringe provision essential for hepatitis C elimination
  • Half of people who inject drugs in Middle East have hepatitis C
  • 90% of injection drug users miss opportunities for HIV or HCV testing
  • Hepatitis B treatment suboptimal in people with HIV in Africa
  • Medicines Patent Pool and Mylan sign agreement to scale up access to first generic version of hepatitis C treatment glecaprevir/pibrentasvir
  • Is this your copy of the infohep news bulletin?

January 2020

  • London: hepatitis C elimination depends on testing scale-up
  • HepCheck screening programme links 80% to hepatitis C care in 4 European countries
  • Peer-led outreach improves uptake of hepatitis C care among homeless and people who use drugs
  • Hepatitis C screening among PrEP users could eliminate hepatitis C infections in gay men in UK
  • How to check drug interactions with hepatitis C drugs
  • Programme provides medical lockers for homeless people to store prescriptions
  • Hepatitis C-positive donors a viable option to expand heart donor pool
  • Egypt screens 1.6 million school students for hepatitis C
  • Is this your copy of the infohep news bulletin?
20202019201820172016201520142013